Targeted treatments in colorectal cancer: state of the art and future perspectives

被引：55

作者：

Arnold, Dirk

Seufferlein, Thomas ^{[1
]}

机构：

[1] Martin Luther Univ Halle Wittenberg, Dept Internal Med 1, D-06120 Halle, Saale, Germany

来源：

GUT | 2010年 / 59卷 / 06期

关键词：

GROWTH-FACTOR RECEPTOR; PHASE-II TRIAL; CETUXIMAB PLUS IRINOTECAN; MONOCLONAL-ANTIBODY CP-751,871; OXALIPLATIN-BASED CHEMOTHERAPY; TYROSINE KINASE INHIBITOR; FACTOR TYPE-1 RECEPTOR; GENE COPY NUMBER; K-RAS; ANTIANGIOGENIC THERAPY;

D O I：

10.1136/gut.2009.196006

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Targeted treatments have generated a lot of hope and hype in the treatment of gastrointestinal tumours. Indeed, the introduction of targeted treatments particularly for colorectal cancer has resulted in substantial improvements in tumour response and progression-free survival of patients. However, it is not fully understood how these agents act in patients, and the preclinical models are not appropriate to predict clinical efficacy. Here the current state of targeted treatments in colorectal cancer is reviewed, focusing on antiepidermal growth factor receptor (EGFR) and antiangiogenic strategies, describing how these agents fit into the therapeutic algorithm of this disease and discussing current understanding of the mechanism of action, biomarkers as well as future therapeutic strategies targeting multiple signalling pathways in colorectal cancer.

引用

页码：838 / 858

页数：21

共 158 条

[1] The mammalian target of rapamycin signaling pathway: Twists and turns in the road to cancer therapy [J].

Abraham, Robert T. ;

Gibbons, James J. .

CLINICAL CANCER RESEARCH, 2007, 13 (11) :3109-3114

[2] Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5 [J].

Adams, C. ;

Totpal, K. ;

Lawrence, D. ;

Marsters, S. ;

Pitti, R. ;

Yee, S. ;

Ross, S. ;

Deforge, L. ;

Koeppen, H. ;

Sagolla, M. ;

Compaan, D. ;

Lowman, H. ;

Hymowitz, S. ;

Ashkenazi, A. .

CELL DEATH AND DIFFERENTIATION, 2008, 15 (04) :751-761

[3] Contribution of bone marrow-derived cells to blood vessels in ischemic tissues and tumors [J].

Aghi, M ;

Chiocca, EA .

MOLECULAR THERAPY, 2005, 12 (06) :994-1005

[4] The insulin-like growth factor type 1 receptor and colorectal neoplasia: insights into invasion [J].

Allison, Andrew S. ;

McIntyre, Margaret A. ;

McArdle, Colin ;

Habib, Fouad K. .

HUMAN PATHOLOGY, 2007, 38 (11) :1590-1602

[5] Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].

Amado, Rafael G. ;

Wolf, Michael ;

Peeters, Marc ;

Van Cutsem, Eric ;

Siena, Salvatore ;

Freeman, Daniel J. ;

Juan, Todd ;

Sikorski, Robert ;

Suggs, Sid ;

Radinsky, Robert ;

Patterson, Scott D. ;

Chang, David D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634

[6] An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors [J].

Amador, ML ;

Oppenheimer, D ;

Perea, S ;

Maitra, A ;

Cusati, G ;

Iacobuzio-Donahue, C ;

Baker, SD ;

Ashfaq, R ;

Takimoto, C ;

Forastiere, A ;

Hidalgo, M .

CANCER RESEARCH, 2004, 64 (24) :9139-9143

[7] Kirsten ras mutations in patients with colorectal cancer:: the 'RASCAL II' study [J].

Andreyev, HJN ;

Norman, AR ;

Cunningham, D ;

Oates, J ;

Dix, BR ;

Iacopetta, BJ ;

Young, J ;

Walsh, T ;

Ward, R ;

Hawkins, N ;

Beranek, M ;

Jandik, P ;

Benamouzig, R ;

Jullian, E ;

Laurent-Puig, P ;

Olschwang, S ;

Muller, O ;

Hoffmann, I ;

Rabes, HM ;

Zietz, C ;

Troungos, C ;

Valavanis, C ;

Yuen, ST ;

Ho, JWC ;

Croke, CT ;

O'Donoghue, DP ;

Giaretti, W ;

Rapallo, A ;

Russo, A ;

Bazan, V ;

Tanaka, M ;

Omura, K ;

Azuma, T ;

Ohkusa, T ;

Fujimori, T ;

Ono, Y ;

Pauly, M ;

Faber, C ;

Glaesener, R ;

de Goeij, AFPM ;

Arends, JW ;

Andersen, SN ;

Lövig, T ;

Breivik, J ;

Gaudernack, G ;

Clausen, OPF ;

De Angelis, P ;

Meling, GI ;

Rognum, TO ;

Smith, R .

BRITISH JOURNAL OF CANCER, 2001, 85 (05) :692-696

[8] Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer:: a phase Ib/II study of the AIO GI Group [J].

Arnold, D. ;

Hoehler, T. ;

Dittrich, C. ;

Lordick, F. ;

Seufferlein, T. ;

Riemann, J. ;

Woell, E. ;

Herrmann, T. ;

Zubel, A. ;

Schmoll, H. -J. .

ANNALS OF ONCOLOGY, 2008, 19 (08) :1442-1449

[9] Role of PIGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1 [J].

Autiero, M ;

Waltenberger, J ;

Communi, D ;

Kranz, A ;

Moons, L ;

Lambrechts, D ;

Kroll, J ;

Plaisance, S ;

De Mol, M ;

Bono, F ;

Kliche, S ;

Fellbrich, G ;

Ballmer-Hofer, K ;

Maglione, D ;

Mayr-Beyrle, U ;

Dewerchin, M ;

Dombrowski, S ;

Stanimirovic, D ;

Van Hummelen, P ;

Dehio, C ;

Hicklin, DJ ;

Persico, G ;

Herbert, JM ;

Communi, D ;

Shibuya, M ;

Collen, D ;

Conway, EM ;

Carmeliet, P .

NATURE MEDICINE, 2003, 9 (07) :936-943

[10] Critical update and emerging trends in epidermal growth factor receptor targeting in cancer [J].

Baselga, J ;

Arteaga, CL .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) :2445-2459

← 1 2 3 4 5 6 7 8 9 10 →